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Patients presenting with ST elevation myocardial infarction (STEMI) are routinely treated with percuta-
neous coronary intervention to restore blood flow in the occluded artery to reduce infarct size (IS).
However, there is evidence to suggest that the restoration of blood flow can cause further damage to the
myocardium through reperfusion injury (RI). Recent research in this area has focused on minimizing
damage to the myocardium caused by RI. Therapeutic hypothermia (TH) has been shown to be beneficial in
animal models of coronary artery occlusion in reducing IS caused by RI if instituted early in an ischemic
myocardium. Data in humans are less convincing to date, although exploratory analyses suggest that there is
significant clinical benefit in reducing IS if TH can be administered at the earliest recognition of ischemia in
anterior myocardial infarction. The Essex Cardiothoracic Centre is the first UK center to have participated
in administering TH in conscious patients presenting with STEMI as part of the COOL-AMI case series
study. In this article, we outline our experience of efficiently integrating conscious TH into our primary
percutaneous intervention program to achieve 18 minutes of cooling duration before reperfusion, with no
significant increase in door-to-balloon times, in the setting of the clinical trial.
Introduction
The primary therapeutic aim of treating patientspresenting with ST elevation myocardial infarction
(STEMI) is to restore blood flow in any occluded coronary
artery at the earliest opportunity to reduce infarct size (IS)
and any associated complications. However, restoring blood
flow can itself lead to further myocardial damage by complex
molecular mechanisms leading to reperfusion injury (RI)
(Kloner, 1993). Therefore, recent research has focused on
ways of minimizing RI.
Therapeutic hypothermia (TH) has been shown to have
beneficial effects on left ventricular myocardial salvage in
animal models of coronary artery occlusion and reperfusion
(Dae et al., 2002; Gotberg et al., 2008; Erlinge, 2011). The
exact mechanism of this benefit remains unclear, although it
has been suggested that at lower core body temperatures,
there is significant reduction in reactive hyperemia (Olive-
crona et al., 2007) and also complex molecular regulation,
including suppression of destructive enzymes, free radicals,
protection of the cellular phospholipid bilayer membrane,
and reduction of intracellular acidosis, resulting in reduced
RI (Dempsey et al., 1987; Chopp et al., 1989). There seems to
be a strong relationship between the timing of hypothermic
temperature achievement and reduction in IS, with 100%
reduction in IS demonstrated if TH is achieved before onset
of ischemia, although of course this is not clinically feasible
(Dixon et al., 2002; Gotberg et al., 2008; Erlinge et al., 2013).
There is no reduction in IS if TH is initiated after reperfusion.
However, some report that up to 80% reduction in IS can be
achieved if TH can be initiated at the earliest recognition
of onset of ischemia and TH achieved before reperfusion
(Dixon et al., 2002; Gotberg et al., 2008, Erlinge et al., 2013).
Therefore, it can be postulated that an efficient transfer
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of patient suffering STEMI and initiating TH simulta-
neously early in the catheter laboratory before reperfusion are
likely to offer the most potential therapeutic benefit of this
treatment.
Studies of TH in humans presenting with STEMI have so
far not demonstrated significant clinical benefit (Dixon et al.,
2002; Erlinge et al., 2013; Erlinge et al., 2014). In the latest
multicenter, randomized controlled trial (Erlinge et al.,
2014), it was shown that TH administered simultaneously
at the time of primary percutaneous intervention (PPCI) did
not reduce the IS significantly. However, exploratory anal-
ysis demonstrated that there was a significant 33% reduction
in IS if TH was administered within 4 hours of symptom
onset in patients with anterior STEMI, and also a significant
reduction in incidence of heart failure was noted in this
group. Future studies on TH will focus on early presenting
anterior STEMI, using more powerful TH devices enabling a
more rapid cooling profile, and to achieve a lower tempera-
ture before reperfusion specifically in these larger infarcts.
Some investigators are also looking at commencement of TH
at an earlier stage, including during ambulance transfer
(Testori, et al., 2013). It has been learnt that an important
aspect of future potential success in this area is efficiency of
the clinical team in administering TH simultaneously with
PPCI. The time of coronary intervention following symptom
onset is vital in dictating prognosis and therefore any delay
following hospital admission should be minimized. In this
article, we focus our discussion on our experience of running
a TH interventional research trial in the setting of patients
presenting with STEMI.
Materials and Methods
The Essex Cardiothoracic Centre (CTC) is a tertiary heart
attack center (HAC) serving a population of 1.7 million in the
county. Every year the center carries out *750 PPCIs. It is
the first UK center that received ethical approval to conduct a
feasibility study of TH in patients presenting with STEMI,
which was sponsored by ZOLL Circulation.
The purpose of the study is as follows:
(1) Investigate the feasibility of administering TH si-
multaneously with PPCI and before reperfusion.
(2) Organize an efficient team to minimize time delays to
TH without compromising patient care.
(3) Controlling shivering in conscious patients who are
actively cooled with an intravenous cooling device.
Recruitment model
Preparation. All 24/7HACs are well trained and effi-
cient in the assessment and treatment of the STEMI patient.
Teamwork in this potentially stressful clinical arena is vital,
and currently the roles and responsibilities of all PPCI team
members are well described and understood. Implement-
ing a TH service in the setting of the STEMI clinical trial
adds further complexity. To ensure efficient enrollment and
cooling, it is paramount that these extra tasks are defined and
delegated.
The day is started by briefing all members of the cardiac
catheter laboratory and research team that if a suitable patient
with STEMI is admitted, he/she will be approached to par-
ticipate in the study. Members of the team are given clear
instructions about their roles during various stages of the
recruitment. All medications, including buspirone, pethi-
dine, and cold intravenous saline, are checked to ensure
adequate supply. The Essex CTC is notified in advance
by the ambulance crew when a patient suffering STEMI
is identified and boarded for transfer with an expected ar-
rival time. The ZOLL Thermogard (TG) cooling machine is
precooled to ensure immediate availability at the optimum
temperature. A typical patient flow diagram is illustrated in
Figure 1.
Stage 1: holding bay/consent. On arrival, the patient is
taken to the holding bay outside the catheter laboratory for
initial assessment by the study team. If hemodynamically
stable, the patient is screened against the inclusion/exclusion
criteria of the ZOLL COOL-AMI EU study. An informed
consent is obtained if the patient decides to take part in the
study and baseline data are collected. Two intravenous access
sites are secured, and the patient is then transferred to the
catheter laboratory for urgent TH and coronary intervention.
FIG. 1. Flow diagram of COOL-AMI EU patient flow and
time aims for completing each part of the study protocol.
IVTM, ZOLL’s Intravascular Temperature Management; PCI,
percutaneous intervention; STEMI, ST elevation myocardial
infarction; TG, The ZOLL Thermogard.
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We aim for the consenting and IV access steps to be com-
pleted within 10 minutes where possible.
Stage 2: catheter laboratory. Once included into the trial,
the focus is on delivering the maximum dose of cooling be-
fore early reperfusion therapy. A Bair Hugger is already
placed on the catheter laboratory table in anticipation for the
patient’s arrival and it is set at 43C. Using warming blankets
on the skin, while cooling within the vena cava with a cooling
catheter, is a recognized strategy for preventing shivering.
For successful and rapid reduction in patient core tempera-
ture, shivering must be prevented. Once shivering occurs,
core temperature will reduce no further and may in fact in-
crease until the shivering is suppressed. The antishiver regi-
men includes 60mg Buspirone orally, with the esophageal
temperature probe inserted simultaneously as it is easier to
pass through the tube when the patient is swallowing, which
minimizes the gag reflex. A bolus of pethidine is then ad-
ministered at a dose of 1mg/kg, followed by intravenous cold
saline to initiate TH. The patient is then wrapped up in
blankets to provide surface warming. We aim to have the
patient on the catheter laboratory table, consented, antishiver
regimen delivered, intravenous iced saline commenced, and
patient ready for cooling catheter insertion within 15 minutes
from arrival. The layout of the cardiac catheter laboratory
during PPCI and simultaneous application of endovascular
TH is shown in Figure 2.
The volume of cold saline administered is dependent
on the suspected area of myocardial infarction. In inferior
myocardial infarction, up to 2 L of cold saline is administered
compared with 1 L in anterior myocardial infarction. The
rationale for this is related to the territory of the myocardium
supplied by the coronary arteries. The right coronary artery
(inferior STEMI) supplies predominantly the right ventricle
and consequently the left ventricle is more susceptible to
volume depletion due to reduced right ventricular contrac-
tility (Cohen et al., 1995), whereas the left anterior des-
cending artery supplies the bulk of the left ventricle and it is
more susceptible to volume overload following a myocardial
infarction (Opie et al., 2006).
Following routine sterilization procedures, the consul-
tant cardiologist secures right femoral vein access to pass the
cooling catheter (ZOLL Quattro catheter). The optimal
catheter position in the inferior vena cava is confirmed under
X-ray guidance. The catheter is then connected to the TG
cooling device to initiate cooling with a set point tempera-
ture of 32C. The esophageal temperature probe is connected
to the TG cooling device, which then displays core body
temperature changes. Peripheral tympanic temperatures are
also obtained at regular intervals according to the study
protocol and this allows checking for any discrepancy in
temperature measurement. We aim for the cooling catheter
to be inserted and cooling commenced within 20 minutes of
hospital arrival.
Arterial access is then obtained preferably through the
right radial artery as there is a lower bleeding risk for the
procedure and it is easier to manage the radial sheath on
the ward and monitor arterial blood gases if required. Base-
line blood is taken and sent off to the laboratory for analysis.
Coronary angiogram images are obtained and the occluded
artery is identified. Following 18 minutes of cooling through
the TG cooling device, the consultant cardiologist proceeds
to appropriate coronary intervention. We aim for a door-to-
balloon (DTB) time in this trial of between 35 and 40 min-
utes, with 18 minutes of cooling before reperfusion.
According to the study shiver management protocol, a
pethidine infusion is set up that can be titrated between 24
and 32mg/h depending on the level of shivering and respi-
ratory drive and administered 15 minutes after the initial
loading dose. The patient is closely monitored during this
active cooling phase to ensure hemodynamic stability and
adequate shiver management, and end tidal CO2 is monitored
through a sensor within the oxygen mask to ensure the patient
has adequate ventilation.
Stage 3: transfer from catheter laboratory to the ward. At
the end of the coronary intervention, the patient is prepared
for transfer to the ward. This phase of the cooling mainte-
nance is vital. The TG cooling device currently needs to be
turned off for transfer, and as a result, patients can increase in
FIG. 2. An illustration of
the catheter laboratory layout
during primary percutaneous
intervention and simultaneous
administration of endovascular
therapeutic hypothermia.
PPCI, primary percutaneous
intervention.
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temperature by about 0.5C within 5 minutes. We have de-
veloped an ice-cold saline protocol where, during trans-
fer, the patient is given a bolus of 250mL of ice-cold saline
to cover the transfer time. We have learnt from our ex-
perience that this intervention minimizes any rebound
temperature gain during the transfer from the catheter
laboratory to the ward. The Essex CTC is well designed for
a quick and efficient transfer between the laboratory and
the coronary care unit, and the average journey time is 3
minutes or less.
Stage 4: ward. On arrival at the ward, the TG cooling
device and the Bair Hugger machine are both switched on
immediately to continue the active cooling therapy to a target
temperature of 32C – 1C. The pethidine infusion rate is
tailored to the patient’s clinical condition. The radial sheath is
kept in situ to monitor arterial blood pressures and blood
gas on the ward. The right femoral vein site is inspected on
regular intervals for any vascular complications. After 3
hours of active cooling, the patient is rewarmed passively.
The TG cooling is turned off, but the esophageal temperature
probe is still kept in situ until core temperature warms to
above 35.5C, defined as normothermia. A cooling curve of a
typical patient enrolled in the study is shown in Figure 3. The
femoral catheter is then removed in a sterile manner, and
manual pressure is applied for 10–15 minutes. At this point,
usual post-PCI care is resumed by the ward team. All steps of
research participation are documented in the medical notes
and formally handed over to the clinical team for continua-
tion of care.
Discussion
It is feasible to deliver efficient TH within the setting of a
clinical trial to patients presenting with STEMI in a large
HAC. The average DTB time for the first 11 patients recruited
into the trial was 38 minutes with an average of 16.5 minutes
of intravenous catheter cooling before reperfusion. This
compares with a DTB mean of 37 minutes for all patients
presenting with STEMI without administration of TH at the
Essex CTC during 2014. This observed 1-minute delay is
favorable to the mean 9-minute delay observed in the CHILL
MI trial, although their sample size was much larger across
multiple sites (Erlinge et al., 2014). More importantly, this
minor delay is well within the 90-minute DTB time target that
PPCI centers are expected to meet (Canadian Cardiovascular
Society et al., 2008).
Evidence from external monitors suggests that our perfor-
mance improved significantly over time in terms of achieving
minimal delay in DTB time and shiver management. This can
be attributed to a combination of factors, including strict ad-
herence to protocol, co-ordination of the team, and clearly
defined roles. Following the enrollment of each patient, we
conduct a debrief session where we discuss different aspects
of the patient treatment and areas for improvement. We, as a
team, got better in speed and efficiency by practicing our roles
meticulously over the duration of the study. There has been no
compromise to the safety of the patients and there have been
no trial-related serious adverse events.
The prevention of shivering is the key to successfully ad-
ministering TH in these patients. The antishivering regimen
provided by the sponsor is a useful guide to ensuring that safe
FIG. 3. Cooling curve of a typical patient recruited to the COOL-AMI trial; mild temperature rise during ward transfer. DTC,
door to consent; DTBPS, door to buspirone, pethidine, ice-cold saline; DTIVTM, door to IVTM; DTB, door-to-balloon.
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doses of antishivering medications are administered and in the
correct order. Early signs of shivering can be identified from
the ECG monitors, where the isoelectric line may demonstrate
signs of microshivering. This then allows the clinical team to
administer bolus doses of pethidine if clinically indicated.
However, the patient’s clinical condition and safety take pri-
ority over shiver control. Therefore, it is essential to monitor
patient’s clinical condition before any pethidine bolus is ad-
ministered. The application of multiple layers of blanket en-
suresmaximum surface warming as the skin is the largest organ
for heat exchange, and if the skin perceives warmth, then it
appears that shivering is minimized.
The efficient transfer of the patient from the catheter labo-
ratory to the ward is another key element to success as this is a
time when active cooling needs to be turned off and therefore
allows the potential for rebound hyperthermia. We introduced
the administration of 250mL of cold saline into our transfer
regime tominimize temperature rebound. In addition, the CCU
is prenotified before transfer to ensure all equipment, including
the Bair Hugger and TG cooling device, can be restarted in-
stantly on patient’s arrival. The continuous presence of a cli-
nician throughout the course of the patient monitoring during
active cooling and passive rewarming adds to the safety of this
trial; however, this may be a challenge in a center with limited
resources.
With a well-trained team within this feasibility trial, it
is possible to deliver 18 minutes of TH to STEMI patients
before PPCI reperfusion without a significant prolongation of
DTB times. This work paves the way for a larger randomized
controlled study where important clinical outcomes, includ-
ing left ventricular IS and function, patient safety, and mor-
tality, can be measured against standard PPCI care.
Conclusion
In summary, RI is associated with an increase in morbidity
and mortality. TH has shown promise particularly in patients
presenting early with anterior STEMI. The delivery of TH in
the conscious patient is challenging, and previous trials have
been criticized by delaying reperfusion to allow for delivery
of TH, the benefits of which may be canceled out by the
adverse effects of lengthening the symptom-to-reperfusion
time. This review outlines our experience at a busy HAC in
delivery of TH in conscious STEMI without delaying re-
perfusion, albeit in the setting of a clinical trial. We hope that
this review will help other centers deliver similar results, thus
giving TH the best chance of succeeding in reducing the
adverse effects of RI in STEMI.
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